154 related articles for article (PubMed ID: 24930407)
1. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
Akamatsu S; Hayes CN; Tsuge M; Murakami E; Hiraga N; Abe H; Miki D; Imamura M; Ochi H; Chayama K;
J Viral Hepat; 2015 Feb; 22(2):166-74. PubMed ID: 24930407
[TBL] [Abstract][Full Text] [Related]
2. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
[TBL] [Abstract][Full Text] [Related]
3. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
4. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
[TBL] [Abstract][Full Text] [Related]
5. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Makokha GN; Ochi H; Amano H; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Gastroenterol; 2017 Jun; 52(6):746-753. PubMed ID: 27822709
[TBL] [Abstract][Full Text] [Related]
6. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
[TBL] [Abstract][Full Text] [Related]
7. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
8. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
[TBL] [Abstract][Full Text] [Related]
9. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
Azakami T; Hayes CN; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Nakamura Y; Kamatani N; Chayama K
J Med Virol; 2011 Jun; 83(6):1048-57. PubMed ID: 21503919
[TBL] [Abstract][Full Text] [Related]
10. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
[TBL] [Abstract][Full Text] [Related]
11. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
[TBL] [Abstract][Full Text] [Related]
12. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H; Imamura M; Nagaoki Y; Kawakami Y; Abe H; Hayes CN; Kan H; Fukuhara T; Kobayashi T; Masaki K; Ono A; Nakahara T; Honda Y; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Hiraga N; Tsuge M; Hiramatsu A; Hyogo H; Aikata H; Takahashi S; Miki D; Ochi H; Ohishi W; Chayama K;
J Gastroenterol; 2014 Dec; 49(12):1548-56. PubMed ID: 24362944
[TBL] [Abstract][Full Text] [Related]
14. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
16. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
Chayama K; Hayes CN; Abe H; Miki D; Ochi H; Karino Y; Toyota J; Nakamura Y; Kamatani N; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H
J Infect Dis; 2011 Jul; 204(1):84-93. PubMed ID: 21628662
[TBL] [Abstract][Full Text] [Related]
17. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
[TBL] [Abstract][Full Text] [Related]
18. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
[TBL] [Abstract][Full Text] [Related]
19. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
[TBL] [Abstract][Full Text] [Related]
20. Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
Zampino R; Alessio L; Marrone A; Stanzione M; Boemio A; Grandone A; Minichini C; Pisaturo M; Starace M; Adinolfi LE; Sagnelli E; Coppola N
Infez Med; 2015 Jun; 23(2):134-9. PubMed ID: 26110293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
